Gulten Emek TUNA, Ceren DINLER AY, Bulent ULUTAS, Gamze Sevri EKREN ASICI, Huseyin VOYVODA

Kanin Parvoviral Enterit’in Klinik Şiddeti ve Prognozunu Değerlendirmede Serum İntestinal Yağ Asidi Bağlayıcı Protein ve Kalprotektin Konsantrasyonlar

Bu çalışma, köpeklerde Parvoviral (CPV) enteritin klinik şiddetini ve prognozunu öngörmede serum intestinal yağ asidi bağlayıcı protein (IFABP) ve kalprotektin (CALP) konsantrasyonlarının kullanılabilirliğinin, diğer belirteçlerle [toplam lökosit sayıları (TLC), C-reaktif protein (CRP) ve prokalsitonin (PCT)] karşılaştırmalı olarak değerlendirmek için gerçekleştirildi. On sağlıklı köpek (CON grubu) ve 40 doğal CPV enteritisli (INF grubu) köpek kullanıldı. INF grubu da hayatta kalan (survivor) ve hayatta kalmayan (non-survivor) olarak ikiye ayrıldı. INF grubundan iki ve CON grubundan bir kez kan örnekleri alındı. Belirli klinik bulgular puanlanarak her hasta için klinik sağlık skoru (CHS) hesaplandı. Hastaneye yatışta (0. saat) INF grubunun serum CRP, IFABP ve plazma PCT konsantrasyonları CON grubundan anlamlı derecede yüksekti. Survivor altgrubu ile karşılaştırıldığında, non-survivor altgrubunun ortalama serum PCT ve IFABP konsantrasyonları, hem 0. saatte hem de tedavi başlangıcından 24 saat sonra (24. saat) önemli ölçüde yüksekti, ortalama TLC ise 24. saatte önemli ölçüde düşüktü. CHS ile serum IFABP (r=0.501; P=0.000) arasındaki korelasyon, değerlendirilen diğer biyobelirteçlerden daha güçlüydü. Alıcı İşletim Karakteristiği eğrisi analizinden elde edilen duyarlılık ve özgüllüğe dayalı olarak, TLC (24. saat) ve serum IFABP (0. saat), CPV enteritinin prognozunu tahmin etmek için bu çalışmanın parametreleri arasında en değerli biyobelirteçler olarak hizmet

Serum Intestinal Fatty Acid-Binding Protein and Calprotectin Concentrations to Assess Clinical Severity and Prognosis of Canine Parvovirus Enteritis

This study was conducted to assess the usefulness of serum intestinal fatty acid-binding protein (IFABP) and calprotectin (CALP) concentrations in comparison with other biomarkers [total leucocyte counts (TLC), C- reactive protein (CRP) and procalcitonin (PCT)] in predicting the clinical severity and prognosis of Canine Parvoviral (CPV) enteritis. Ten healthy dogs (CON group) and 40 dogs with natural CPV enteritis (INF group) were used. The INF group was also divided into survivor and non-survivor. Blood samples were collected twice in the INF group and once in the CON group. The clinical health score (CHS) was calculated for each patient by scoring certain clinical findings. Serum CRP and IFABP, and plasma PCT concentrations of the INF group at hospital admission (0 h) were significantly higher than in the CON group. Compared to the survivor subgroup, mean serum PCT and IFABP concentrations in the non-survivor subgroup were significantly higher at both 0 h and after initiation of treatment (24 h), while the mean TLC was significantly lower at 24 h. The correlation between CHS and serum IFABP (r=0.501; P=0.000) was stronger than other biomarkers evaluated. Based on the sensitivity and specificity from the Receiver Operating Characteristic curve analysis, TLC (24 h) and serum IFABP (0 h) serve as the most valuable biomarkers among the parameters in this study to predict the prognosis of CPV enteritis

PDF

___

1. Mylonakis ME, Kalli I, Rallis TS: Canine parvoviral enteritis: An update on the clinical diagnosis, treatment, and prevention. Vet Med, 7, 91-100, 2006. DOI: 10.2147/VMRR.S80971
2. Prittie J: Canine parvoviral enteritis: A review of diagnosis, management, and prevention. J Vet Emerg Crit Care, 14 (3): 167-176, 2004. DOI: 10.1111/ j.1534-6935.2004.04020.x
3. Vannamahaxay S, Chuammitri P: Update on canine Parvovirus: Molecular and genomic aspects, with emphasis on genetic variants affecting the canine host. Kafkas Univ Vet Fak Derg, 23 (5): 847-856, 2017. DOI: 10.9775/kvfd.2017.17673
4. Meunier PC, Cooper BJ, Appel MJ, Slauson DO: Pathogenesis of canine parvovirus enteritis: The importance of viremia. Vet Pathol, 22 (1): 60-71, 1985. DOI: 10.1177/030098588502200110
5. Dossin O, Rupassara SI, Weng HY, Williams DA, Garlick PJ, Schoeman JP: Effect of parvoviral enteritis on plasma citrulline concentration in dogs. J Vet Intern Med, 25 (2): 215-221, 2011. DOI: 10.1111/j.1939-1676. 2010.0671.x
6. Alves F, Prata S, Nunes T, Gomes J, Aguiar S, da Silva FA, Tavares L, Almeida V, Gil S: Canine parvovirus: A predicting canine model for sepsis. BMC Vet Res, 16 (1): 199, 2020. DOI: 10.1186/s12917-020-02417-0
7. Mazzaferro EM: Update on canine parvoviral enteritis. Vet Clin North Am Small Anim Pract, 50 (6): 1307-1325, 2020. DOI: 10.1016/j. cvsm.2020.07.008
8. Eregowda CG, De UK, Singh M, Prasad H, Sarma K, Roychoudhury P, Rajesh JB, Patra MN, Behera SK: Assessment of certain biomarkers for predicting survival in response to treatment in dogs naturally infected with canine parvovirus. Microb Pathog, 149:104485, 2020. DOI: 10.1016/j. micpath.2020.104485
9. Kocaturk M, Martinez S, Eralp O, Tvarijonaviciute A, Ceron J, Yilmaz Z: Prognostic value of serum acute‐phase proteins in dogs with parvoviral enteritis. J Small Anim Pract, 51 (9): 478-483, 2010. DOI: 10.1111/j.1748- 5827.2010.00965.x
10. McClure V, van Schoor M, Thompson PN, Kjelgaard-Hansen M, Goddard A: Evaluation of the use of serum C-reactive protein concentration to predict outcome in puppies infected with canine parvovirus. J Am Vet Med Assoc, 243 (3): 361-366, 2013. DOI: 10.2460/ javma.243.3.361
11. Kubesy AA, Rakha GM, Salem SI, Jaheen AH: Altered blood procalcitonin, C-reactive protein, and leucocytes count in association with canine parvovirus (CPV) enteritis. Comp Clin Pathol, 28 (4): 1095- 1099, 2019. DOI: 10.1007/s00580-019-02941-y
12. Lee H: Procalcitonin as a biomarker of infectious diseases. Korean J Intern Med, 28(3): 285-291, 2013. DOI: 10.3904/kjim.2013.28.3.285
13. Goggs R, Milloway M, Troia R, Giunti M: Plasma procalcitonin concentrations are increased in dogs with sepsis. Vet Rec Open, 5 (1): e000255, 2018. DOI: 10.1136/vetreco-2017-000255
14. Troia R, Giunti M, Goggs R: Plasma procalcitonin concentrations predict organ dysfunction and outcome in dogs with sepsis. BMC Vet Res, 14 (1): 111, 2018. DOI: 10.1186/s12917-018-1427-y
15. Easley F, Holowaychuk MK, Lashnits EW, Nordone SK, Marr H, Birkenheuer AJ: Serum procalcitonin concentrations in dogs with induced endotoxemia. J Vet Intern Med, 34 (2): 653-658, 2020. DOI: 10.1111/jvim.15711
16. Jung SY, Park YB, Ha YJ, Lee KH, Lee SK: Serum calprotectin as a marker for disease activity and severity in adult-onset Still’s disease. J Rheumatol, 37 (5): 1029-1034, 2010. DOI: 10.3899/jrheum.091120
17. Heilmann RM, Ruaux CG, Grützner N, Cranford SM, Bridges CS, Steiner JM: Biological variation of serum canine calprotectin concentrations as measured by ELISA in healthy dogs. Vet J, 247, 61-64, 2019. DOI: 10.1016/j.tvjl.2019.03.002
18. Dhas DBB, Bhat BV, Gane DB: Role of calprotectin in infection and inflammation. Curr Pediatr Res, 16 (2): 83-94, 2012.
19. Heilmann RM, Jergens AE, Ackermann MR, Barr JW, Suchodolski JS, Steiner JM: Serum calprotectin concentrations in dogs with idiopathic inflammatory bowel disease. Am J Vet Res, 73 (12): 1900-1907, 2012. DOI: 10.2460/ajvr.73.12.1900
20. Thames BE, Barr JW, Suchodolski JS, Steiner JM, Heilmann RM: Prospective evaluation of S100A12 and S100A8/A9 (calprotectin) in dogs with sepsis or the systemic inflammatory response syndrome. J Vet Diagn Invest, 31 (4): 645-651, 2019. DOI: 10.1177/1040638719856655
21. Aydemir C, Dilli D, Oguz SS, Ulu HO, Uras N, Erdeve O, Dilmen U: Serum intestinal fatty acid binding protein level for early diagnosis and prediction of severity of necrotizing enterocolitis. Early Hum Dev, 87 (10): 659-661, 2011. DOI: 10.1016/j.earlhumdev.2011.05.004
22. Adriaanse MPM, Tack GJ, Passos VL, Damoiseaux JGMC, Schreurs MWJ, Van Wijck K, Riedl RG, Masclee AMM, Buurman WA, Mulder CJJ, Vreugdenhil ACE: Serum I‐FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating auto- antibodies. Aliment Pharmacol Ther, 37 (4): 482-490, 2013. DOI: 10.1111/ apt.12194
23. Lau E, Marques C, Pestana D, Santoalha M, Carvalho D, Freitas P, Calhau C: The role of I-FABP as a biomarker of intestinal barrier dysfunction driven by gut microbiota changes in obesity. Nutr Metab, 13: 31, 2016. DOI: 10.1186/s12986-016-0089-7
24. Gulersoy E, Ok M, Yildiz R, Koral E, Ider M, Sevinc M, Zhunushova A: Assessment of intestinal and cardiac-related biomarkers in dogs with parvoviral enteritis. Pol J Vet Sci, 23 (2): 211-219, 2020. DOI: 10.24425/ pjvs.2020.133635
25. Hauptman JG, Walshaw R, Olivier NB: Evaluation of the sensitivity and specificity of diagnostic criteria for sepsis in dogs. Vet Surg, 26 (5): 393-397, 1997. DOI: 10.1111/j.1532-950X.1997.tb01699.x
26. Martin V, Najbar W, Gueguen S, Grousson D, Eun HM, Lebreux B, Aubert A: Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial. Vet Microbiol, 89 (2-3): 115-127, 2002. DOI: 10.1016/S0378-1135(02)00173-6
27. Goddard A, Leisewitz AL: Canine parvovirus. Vet Clin North Am Small Anim Pract, 40 (6), 1041-1053, 2010. DOI: 10.1016/j.cvsm.2010.07.007 28. Judge P: Management of the patient with canine parvovirus enteritis. Vet Educ, 21, 5-11, 2015.
29. Chan YH: Biostatistics 104: Correlational analysis. Singapore Med J, 44 (12): 614-619, 2003.
30. Plunkett SJ: Gastrointestinal emergencies. Emergency Procedures for the Small Animal Veterinarian, 133-194, 2000. DOI: 10.1016/B978-0-7020- 2487-0.50011-3
31. Goddard A, Leisewitz AL, Christopher MM, Duncan NM, Becker PJ. Prognostic usefulness of blood leukocyte changes in canine parvoviral enteritis. J Vet Intern Med, 22 (2): 309-316, 2008. DOI: 10.1111/j.1939- 1676.2008.0073.x
32. Schoeman JP, Goddard A, Leisewitz AL: Biomarkers in canine parvovirus enteritis. N Z Vet J, 61 (4): 217-222, 2013. DOI: 10.1080/ 00480169.2013.776451
33. Decembrino L, De Amici M, Pozzi M, De Silvestri A, Stronati M: Serum calprotectin: A potential biomarker for neonatal sepsis. J Immunol Res, 147973, 2015. DOI: 10.1155/2015/147973
34. Terrin G, Passariello A, Manguso F, Salvia G, Rapacciuolo L, Messina F, Raimondi F, Canani RB: Serum calprotectin: An antimicrobial peptide as a new marker for the diagnosis of sepsis in very low birth weight newborns. Clin Dev Immunol, 2011:291085, 2011. DOI: 10.1155/2011/291085